| Code | CSB-RA008759MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Radretumab, targeting fibronectin 1 (FN1), a high molecular weight glycoprotein component of the extracellular matrix. FN1 plays critical roles in cell adhesion, migration, wound healing, and embryonic development through its interactions with integrins and other matrix components. Aberrant FN1 expression and alternative splicing patterns are implicated in various pathological conditions, including fibrotic diseases, cancer progression, and metastasis, where it contributes to tumor cell invasion, angiogenesis, and the formation of a permissive tumor microenvironment.
Radretumab, the reference antibody, is a human-murine chimeric IgG1 monoclonal antibody that specifically recognizes the extra domain B (EDB) of fibronectin, a splice variant predominantly expressed in tumor vasculature and remodeling tissues but largely absent in normal adult tissues. This biosimilar antibody provides researchers with a valuable tool for investigating FN1-mediated processes in oncology, fibrosis, and vascular biology research, enabling studies of extracellular matrix remodeling and tumor microenvironment dynamics.
There are currently no reviews for this product.